Divi’s Lab share price tanks over 4% as SBI Mutual Fund cuts stake in the firm; check key details

SBI Mutual Fund, in an exchange filing on February 20, said that it sold 140,560 shares, representing 0.0529% of the paid-up share capital of the company on February 19 under its various schemes.

Following this, the final holding of SBI Mutual Fund, under its various schemes, as at the close of business hours on February 19, was 1,33,99,732 shares, which is 5.0476% of the paid-up share capital of Divi's Labs. Ahead of the stake sale, SBI Mutual Fund held a 1,35,40,292 or 5.1005% stake in the blue-chip pharma company.

Divi’s Lab shares tanked 4.32% to close at ₹5,718 per share on Friday. During the intraday trade, shares of the firm were trading 3.25% lower at ₹5782.25 per share on BSE.

Active pharmaceutical ingredients manufacturer Divi's Laboratories posted a 64.52% increase in its consolidated profit after tax (PAT) to ₹589 crore in the quarter ended December 2024, the company said in an exchange filing. In the year-ago period, the net profit was ₹358 crore.

Revenue from operations surged 25% to ₹2,319 crore in the third quarter of the financial year 2024-25, compared to ₹1,855 crore a year back.

EBITDA (earnings before interest, taxes, depreciation and amortisation) rose 52% to ₹743 crore in the latest October-December quarter as compared to ₹489 crore in Q3 FY24. The EBITDA margin was at 32% vs 26.4% in the same period the previous year.

For the nine months ended December 31, 2024, the pharma major reported a 43.97% jump in net profit to ₹1,529 crore, as against ₹1,062 crore in the same period a year ago.

In 9M FY25, "The company earned a consolidated total income of ₹7,041 crore as against a consolidated total income of ₹5,804 crore during the corresponding nine-month period of the previous year. PBT for the current nine months period accounted to ₹2,052 crore as against ₹1,450 crore for the corresponding nine months period of the previous year," Divi's Lab said.